Abstract
Leishmaniasis affects about 12 million people worldwide and includes diseases ranging from the localized cutaneous form to the visceral one, which is the most severe manifestation, with high human mortality and morbidity. Visceral leishmaniasis (VL) is mainly characterized by a chronic inflammatory response, and although it is a result of a change in the balance of effector and regulatory…